Rock Star Growth Puts Castle Biosciences (NASDAQ:CSTL) In A Position To Use Debt

Simply Wall StJan 6 09:10 ET

Castle Biosciences Receives Assay Approval From The New York State Department Of Health For Its TissueCypher Barrett's Esophagus Test

BenzingaJan 6 07:04 ET

VSTM Up as NDA for Ovarian Cancer Combo Gets FDA's Priority Review Tag

Zacks Jan 2 09:15 ET

Castle Biosciences Price Target Maintained With a $41.00/Share by Stephens & Co.

Dow JonesJan 2 08:10 ET · Ratings

Beyond The Numbers: 7 Analysts Discuss Castle Biosciences Stock

BenzingaJan 2 08:02 ET

Castle Biosciences Analyst Ratings

BenzingaJan 2 07:56 ET · Ratings